CURE vs RXD: which held to its multiple?
Over three months against its own daily promise, CURE finished 2.5 points short and RXD 2.0 points over. Direxion Daily Healthcare Bull 3X ETF and ProShares UltraShort Health Care.
CURE returned +13.8% while 3 times XLV's move would have been +17.9%
RXD returned −11.0% while −2 times XLV's move would have been −11.9%
CURE among the 470 leveraged ETFs, long, over three months
RXD among the 125 inverse ETFs over three months
A percentile among the 470 leveraged ETFs, long, over three months. RXD is a percentile among the 125 inverse ETFs over three months, a different set, so the two marks are not on one scale. It is a position in a set, not a rating, and neither end of it is a recommendation. All leveraged ETFs ranked by it → How it is computed →
Performance, window by window
| Total return | Multiple would give | Difference | ||||
|---|---|---|---|---|---|---|
| Window | CURE | RXD | CURE | RXD | CURE | RXD |
| 1 month | −3.6% | +1.7% | −2.6% | +1.7% | −1.0 pts | 0.0 pts |
| 3 months | +13.8% | −11.0% | +17.9% | −11.9% | −4.1 pts | +0.9 pts |
| 6 months | +38.8% | −24.2% | +44.8% | −29.9% | −6.0 pts | +5.7 pts |
| 1 year | +56.9% | −32.5% | +69.1% | −46.1% | −12.2 pts | +13.6 pts |
| 3 years | +51.9% | −38.2% | +112.5% | −75.0% | −60.6 pts | +36.8 pts |
| Since launch CURE Jun 2011 · RXD Jan 2010 | +2815.8% | −99.2% | not meaningful | not meaningful | not meaningful | not meaningful |
CURE and RXD over each window. Every figure is an ETFIQ calculation with distributions reinvested. Source: ETFIQ. Open the live comparison on ETFIQ →
On the same fields
CURE and RXD on the same fields, as of Sep 30, 2026. Source: ETFIQ.
CURE in plain words
Three months to Sep 30, 2026: CURE returned +13.8% where its own daily promise gave +16.3%, 2.5 points short. Read the multiple against the whole window instead and 3 times XLV's 6.0% implies +17.9%, which makes CURE look 4.1 points short. 1.6 of that is daily compounding, which happens to any 3 times fund over the same path, and the rest is the fund. CURE aims to return +3 times XLV's move each day, then resets. Over one day it does that. Over longer, the daily results compound, so the total is not +3 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more. XLV moved at 18% annualized over that window. That is what decides how far the two figures separate: the same fund on a calm underlying and a violent one is a different product.
RXD in plain words
Three months to Sep 30, 2026: RXD returned −11.0% where its own daily promise gave −13.0%, 2.0 points over. Read the multiple against the whole window instead and −2 times XLV's 6.0% implies −11.9%, which makes RXD look 0.9 points over. 1.1 of that is daily compounding, which happens to any −2 times fund over the same path, and the rest is the fund. RXD aims to return -2 times XLV's move each day, then resets. Over longer, the daily results compound, so the total is not -2 times the period's move: in a market that falls and comes back it is reliably less, and in a steady run it can be more.
Questions people ask
- Which came closer to its stated multiple, CURE or RXD?
- Over the window to Sep 30, 2026, CURE finished 4.1 points from what its multiple implies and RXD finished 0.9 points from its own, so RXD came closer. Neither figure predicts the next window: it depends on how much the underlying moves about.
- Are CURE and RXD levered on the same thing?
- Yes. Both are levered on health care, CURE at +3 times and RXD at -2 times the daily move.
- Which one decays faster, CURE or RXD?
- Decay follows how much the underlying moves about. Over this window CURE’s moved at 18% annualized and RXD’s at 18%, so CURE has the rougher ride and, at the same multiple, loses more to compounding.
- Can I hold CURE or RXD for a year?
- Both reset every day, so the multiple in the name applies to a single day and the daily results compound. Over a year the total is not the multiple times the year’s move, and in a market that falls and comes back it is reliably less. ETFIQ makes no recommendation either way.
ETFIQ links to the documents behind every figure. It is not affiliated with any issuer, and a link is not an endorsement. A comparison is not a recommendation.
ETFIQ, CURE against RXD, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/cure-vs-rxd
Free to use with attribution. Every figure is calculated from a named public source; the method is at etfiq.com/methodology.
Cite this page. ETFIQ, CURE against RXD, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/cure-vs-rxd Free to use with attribution; the underlying files are at Open data.
Other forms
- Plain
- ETFIQ, CURE against RXD, data as of Sep 30, 2026. https://etfiq.com/compare/leverage/cure-vs-rxd
- APA
- ETFIQ. (Sep 30, 2026). CURE against RXD. Retrieved from https://etfiq.com/compare/leverage/cure-vs-rxd
- Markdown
- [CURE against RXD (ETFIQ, Sep 30, 2026)](https://etfiq.com/compare/leverage/cure-vs-rxd)